News - dabrafenib, Pharmaceutical


Current filters:


Popular Filters

Australia’s PBS lists new medicines and increases cost threshold to A$20 million

Australia’s PBS lists new medicines and increases cost threshold to A$20 million


The Australian Federal Minister for Health, Peter Dutton, has announced that the cost of 50 new and amended…


FDA approves two GSK melanoma drugs and bioMerieux companion diagnostic


The US Food and Drug Administration yesterday (May 29) approved two new oral drugs from UK pharma giant…

BioMerieuxdabrafenibGlaxoSmithKlineMekinistNorth AmericaOncologyPharmaceuticalRegulationTafinlartrametinib

Treatment landscape for thyroid carcinoma will change dramatically through 2021; report


Through 2021, the treatment landscape for thyroid carcinoma will change dramatically in the USA and Europe…

BayerdabrafenibEisaiEuropeGlaxoSmithKlinelenvatinibMarkets & MarketingNexavarNorth AmericaOncologyOXiGENEPharmaceuticalRochetrametinibZelborafZybrestat

GlaxoSmithKline initiates Ph III study to test dabrafenib and trametinib combo for BRAF positive melanoma


UK pharma giant GlaxoSmithKline (LSE: GSK) has initiated COMBI-AD, a Phase III study evaluating the combination…

BiotechnologydabrafenibGlaxoSmithKlineJapan TobaccoOncologyPharmaceuticalResearchtrametinib

Yervoy and Zelboraf accounted for two-thirds of malignant melanoma drug market in 2011; report


The launches of Bristol-Myers Squibb's (NYSE: BMY) immunotherapy Yervoy (ipilimumab) and Roche (ROG:…

Bristol-Myers SquibbdabrafenibGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRochetrametinibYervoyZelboraf

GlaxoSmithKline files for EU and US approval for dabrafenib and trametinib


UK pharma giant GlaxoSmithKline (LSE: GSK) last week submitted regulatory filings in the European Union…

dabrafenibEuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationtrametinib

MEK inhibitors: new weapon in the fight against melanoma


Cancer cell signaling has long been an attractive target for oncology drug development. Increased activation…


More news from ASCO meeting


More positive late-stage clinical data continued to roll out at the Annual Meeting of the American Society…

AlimtaBayerdabrafenibEli LillyGlaxoSmithKlineOncologyPharmaceuticalregorafenibResearchtrametinib

Malignant melanoma drug market to grow more than seven-fold to $1.5 billion in 2020


The market for malignant melanoma drugs is forecast to expand more than seven-fold over the next decade,…

dabrafenibGlobalMarkets & MarketingOncologyPharmaceuticaltrametinibYervoyZelboraf

Back to top